More Research, Less Cancer: £250m raised to transform the future of cancer research / Cancer Research UK
Charlotte Mathé / cancerresearchuk - We’ve reached an incredible moment - £250m raised for our More Research, Less Cancer campaign. This milestone brings us more than halfway to our £400m goal and accelerates our mission to prevent, detect and treat cancer earlier and more effectively. The p…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #oncology
Tuesday, February 24, 2026, 1:24 pm / permalink 19675 / 53 stories in 14 days
FDA Launches Framework to Accelerate Individualized Therapies for Ultra-Rare Diseases 2026 / OncoDaily
oncodaily - The U.S. Food and Drug Administration (FDA) has released groundbreaking draft guidance introducing a new regulatory framework designed to accelerate the development and approval of individualized therapies for patients with […]
#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda
Tuesday, February 24, 2026, 12:25 pm / permalink 19669 / 6 stories in 14 days
Gilead to acquire cell therapy manufacturer for $7.8B / Beckers
Paige Twenter / beckershospitalreview - In a deal worth $7.8 billion, Gilead Sciences has entered a definitive agreement to acquire Arcellx, a biotech company developing a cell therapy for multiple myeloma. Gilead announced the acquisition agreement a few months after Arcellx published positive…
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #fda #oncology
Monday, February 23, 2026, 4:23 pm / permalink 19605 / 7 stories in 15 days
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin / ESMO
esmo - Findings from the KEYNOTE-905/EV-303 study
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology
Monday, February 23, 2026, 2:22 am / permalink 19558 / 15 stories in 16 days
Data and Decisions in Advanced NSCLC at the 2026 TTLC Symposia – IASLC / OncoDaily
oncodaily - International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn: “2026 TTLC Symposia Event Data and Decisions in Advanced NSCLC The treatment landscape for advanced NSCLC is evolving […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology
Monday, February 23, 2026, 2:22 am / permalink 19557 / 23 stories in 16 days
A novel C. diff vaccine shows promise / Beckers
Mariah Taylor / beckershospitalreview - Nashville, Tenn.-based Vanderbilt Health researchers have developed a promising novel vaccine to treat Clostridioides difficile infections. Previous vaccine strategies targeted the bacterium’s primary toxins, according to a Feb. 18 system news release. Th…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #vaccinesafety
Saturday, February 21, 2026, 7:21 am / permalink 19520 / 2 stories in 18 days
Novartis signs macrocyclic deal with Unnatural Products for $100M upfront / Endpoints
Kyle LaHucik / endpoints - Novartis will pay $100 million upfront to tap into a macrocyclic peptide platform from Unnatural Products, a deal that could lead to new cardiovascular disease medicines. The move allows the Swiss pharma giant to delve ...
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment
Saturday, February 21, 2026, 6:22 am / permalink 19517 / 2 stories in 18 days
Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA / MedCity
Frank Vinluan / medcitynews - The FDA asked for more data to determine whether Disc Medicine’s bitopertin is benefiting patients with erythropoietic protoporphyria, a rare blood disorder. Analysts say it’s a surprising delay considering bitopertin is one of the first drugs in a new FD…
#healthcare #pharmaceuticals #biotech #drugdevelopment #fda
Saturday, February 21, 2026, 6:22 am / permalink 19516 / 5 stories in 18 days
Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks / Nature
Kellen K. Petersen / nature - Nature Medicine, Published online: 19 February 2026; doi:10.1038/s41591-026-04206-yPlasma p-tau217 tests used to develop clocks that predict when cognitively unimpaired individuals would develop symptoms of Alzheimerʼs disease.
#healthcare #publichealth #biotech #drugdevelopment #fda #medicaldevices
Saturday, February 21, 2026, 2:22 am / permalink 19513 / 13 stories in 18 days
'Universal' nasal-spray vaccine protects against viruses, bacteria and allergens in mice / LiveScience
livescience - In an early animal test, a new nasal-spray vaccine has shown promise against a variety of germs and a common allergen, scientists report.
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #vaccinesafety
Friday, February 20, 2026, 5:22 pm / permalink 19489 / 3 stories in 18 days
Your Cat May Share the Same Cancer Genes as You, and Offer Clues for Treatment / Discover
discovermagazine - Learn how cats and humans can share key cancer mutations — and why those similarities could guide future treatment research.
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #oncology
Thursday, February 19, 2026, 9:23 pm / permalink 19449 / 3 stories in 19 days
Immune cells from pediatricians help uncover an antibody cocktail against RSV and hMPV / Medical Express
medicalxpress - Researchers in China recently published a study in Science Translational Medicine describing a new antibody cocktail for protection against two common viruses. The proposed preventative treatment consists of antibodies identified in pediatricians who have…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #infanthealth
Thursday, February 19, 2026, 12:24 pm / permalink 19427 / 3 stories in 19 days
FDA formalizes one pivotal trial policy via NEJM perspective / Endpoints
Zachary Brennan / endpoints - Top FDA officials said that a single pivotal trial requirement will be the “new default standard” for drug approvals, a move that goes beyond the agency’s prior discretion around not requiring two trials. In a ...
#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda
Thursday, February 19, 2026, 11:24 am / permalink 19422 / 3 stories in 19 days
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine / NYT
Christina Jewett and Rebecca Robbins / nytimes - Moderna said it had held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #vaccinesafety
Wednesday, February 18, 2026, 9:23 am / permalink 19353 / 11 stories in 21 days
Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test / MedCity
Frank Vinluan / medcitynews - In the first of two Phase 3 tests, Ocular Therapeutix’s Axpaxli met the main goal of helping maintain vision in patients with the wet form of age-related macular degeneration. The Ocular drug was compared to Eylea, a blockbuster wet AMD drug marketed by R…
#healthcare #pharmaceuticals #biotech #drugdevelopment #fda
Tuesday, February 17, 2026, 9:22 pm / permalink 19334 / 3 stories in 21 days
Lilly appeals retatrutide classification ruling in case that could impact compounders / Endpoints
Alexis Kramer / endpoints - Eli Lilly is challenging a decision over how the FDA classified its experimental, next-gen obesity shot, in a case that could affect the ability of compounders to rival it. On Thursday, Lilly filed a notice ...
#obesity #healthcare #pharmaceuticals #elililly #weightloss #publichealth #drugdevelopment #fda #digitalhealth
Saturday, February 14, 2026, 12:21 pm / permalink 19191 / 15 stories in 24 days
HPV cancer vaccine slows tumor growth and extends survival in preclinical model / Medical Express
medicalxpress - Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design: Performance depends not only on vaccine components but also on vaccine structure. After proving this concept across multiple studies, the…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, February 14, 2026, 5:21 am / permalink 19182 / 5 stories in 25 days
Studies test whether gene-editing can fix high cholesterol. For now, take your medicine / Medical Express
medicalxpress - Scientists are testing an entirely new way to fight heart disease: a gene-editing treatment that might offer a one-time fix for high cholesterol.
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, February 14, 2026, 3:21 am / permalink 19179 / 4 stories in 25 days
Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B / MedCity
Frank Vinluan / medcitynews - Orna Therapeutics brings Eli Lilly an in vivo cell therapy ready for Phase 1 testing as a potential treatment for autoimmune diseases. Lilly is now the latest pharma company to use M&A to enter this growing field, following deals made in the past year by …
#healthcare #pharmaceuticals #elililly #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment
Saturday, February 14, 2026, 3:21 am / permalink 19178 / 9 stories in 25 days
Sanofi's Paul Hudson out, with Belén Garijo to step in as new CEO / Endpoints
Reynald Castañeda / endpoints - Paul Hudson is stepping down from his post as CEO of Sanofi, and his last day will be Feb. 17. The French drugmaker's board decided not to renew Hudson's mandate on ...
#healthcare #pharmaceuticals #biotech #drugdevelopment
Saturday, February 14, 2026, 3:20 am / permalink 19177 / 3 stories in 25 days